MARKET

CBIO

CBIO

Catalyst Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.53
-0.11
-1.66%
After Hours: 6.65 +0.12 +1.84% 16:21 01/15 EST
OPEN
6.67
PREV CLOSE
6.64
HIGH
6.75
LOW
6.31
VOLUME
332.06K
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
3.430
MARKET CAP
144.30M
P/E (TTM)
-2.1075
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time.
GlobeNewswire · 2d ago
Is CBIO A Good Stock To Buy Now?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Catalyst Biosciences In...
Insider Monkey · 12/16/2020 03:28
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 12/11/2020 20:30
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62 Annual American Society of Hematology (ASH) meeting, held virtually December 5-8, 2020, highlighting its Phase 3 Study, Crimson 1. The study will evaluate Marzeptacog alfa (activated) - or MarzAA, the Company's subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa).
GlobeNewswire · 12/07/2020 13:00
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
GlobeNewswire · 12/07/2020 13:00
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held virtually December 5-8, 2020, highlighting its Phase 3 Study, Crimson 1. The study will evaluate Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa). In the poster, entitled “The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors,” Linda Neuman, MD, vice president of clinical development at Catalyst Biosciences, presented the rationale and design of the currently enrolling trial.The Phase 3 study is an open-label, global, multi-center, randomized, cross-over study to evaluate the efficacy and safety of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital Hemophilia A or B with inhibitors, compared to Standard of Care. The study will enroll approximately 60 subjects to treat 244 eligible bleeding episodes with each treatment. The primary endpoint for the trial is the percentage of treated bleeds resulting in effective hemostasis at the 24-hour timepoint. The objective of the trial is to demonstrate non-inferiority of MarzAA compared to Standard of Care.“MarzAA is the only SQ delivered therapy in development for on-demand treatment of bleeding events and could become an important addition to the treatment landscape for patients,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We’re looking forward to announcing our continued progress.”About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare hematologic and complement-mediated disorders. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about Catalyst’s plans for a Phase 3 study of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, the potential for MarzAA to effectively and therapeutically treat hemophilia subcutaneously, and the Company’s collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19 and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s quarterly report filed with the Securities and Exchange Commission on November 5, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.Contact:Ana Kapor Catalyst Biosciences, Inc. investors@catbio.com
GlobeNewswire · 12/07/2020 13:00
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time.
GlobeNewswire · 12/03/2020 21:02
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time.
GlobeNewswire · 12/03/2020 21:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBIO. Analyze the recent business situations of Catalyst Biosciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBIO stock price target is 20.25 with a high estimate of 23.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 16.19M
% Owned: 73.24%
Shares Outstanding: 22.10M
TypeInstitutionsShares
Increased
33
1.81M
New
19
-500.00K
Decreased
20
1.23M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Independent Director
Augustine Lawlor
President/Chief Executive Officer/Director
Nassim Usman
Chief Financial Officer
Clinton Musil
Senior Vice President
Charles Democko
Other
Howard Levy
Vice President
Arwa Shurrab
Independent Director
Errol De Souza
Independent Director
Andrea Hunt
Other
Jamie Siegel
Independent Director
Geoffrey Ling
Independent Director
Sharon Tetlow
Independent Director
Edward Williams
Independent Director
Fei Ling Shiu
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
08/04/2015
Dividend USD 0.5692
08/20/2015
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CBIO
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Catalyst Biosciences Inc stock information, including NASDAQ:CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.